GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Float Percentage Of Total Shares Outstanding

HBPCF (Helix BioPharma) Float Percentage Of Total Shares Outstanding : 93.46% (As of Mar. 26, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Helix BioPharma's float shares is 49.55 Mil. Helix BioPharma's total shares outstanding is 53.02 Mil. Helix BioPharma's float percentage of total shares outstanding is 93.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Helix BioPharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Helix BioPharma's Institutional Ownership is 0.00%.

Helix BioPharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Helix BioPharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=49.55/53.02
=93.46%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
TSXV:SHRX TSXV:NRX XCNQ:GLAB TSX:SVA XCNQ:DTC TSX:MBX TSXV:TTI TSXV:GSD NEOE:BMND TSXV:COV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
HBP0:Germany HBP:Canada
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Website
https://www.helixbiopharma.com
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.